stock delisting
AnPac Bio Receives Nasdaq Delisting Notice
The firm previously received notification from Nasdaq that it no longer met multiple minimum listing requirements for the exchange.
Interpace Biosciences Receives Nasdaq Delisting Notice, Initiates Restructuring
The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.
T2 Biosystems Regains Compliance With Nasdaq Listing Requirements
In April the firm received notice that it wasn't in compliance because its common stock didn't maintain a minimum bid price of $1.00 for 30 consecutive business days.
T2 Biosystems Receives Nasdaq Warning Letter
The Lexington, Massachusetts-based company also terminated a purchase agreement and raised the amount in it may raise in a public offering of its common stock to $95.
Genetic Technologies Receives Nasdaq Delisting Notification
The company will not be allowed to submit another plan for meeting the Nasdaq's listing requirements.
Sep 30, 2019
Nasdaq Warns Biocept Over Listing Requirement
Apr 26, 2019
Precipio to Effect 1-for-15 Reverse Stock Split
Jan 18, 2019
NantHealth Receives Nasdaq Delisting Notice
Jan 17, 2018
OpGen to Execute 1-for-25 Reverse Stock Split
Jul 24, 2017
Genetic Technologies Facing Nasdaq Delisting
Jun 22, 2017
OpGen Warned by Nasdaq of Non-Compliance
May 15, 2017
OpGen Falls Short on Nasdaq Listing Requirement
Apr 13, 2017
Interpace Diagnostics Regains Nasdaq Compliance
Dec 28, 2016
Interpace Effecting a 1-for-10 Reverse Stock Split
Nov 30, 2016
Interpace Diagnostics Faces Nasdaq Delisting
Oct 10, 2016